Related Experiment Video
Updated: Aug 1, 2025

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection
Published on: November 10, 2021
Dickkopf-1 Acts as a Profibrotic Mediator in Progressive Chronic Kidney Disease
Yung-Chien Hsu1,2, Cheng-Chih Chang3, Ching-Chuan Hsieh4
1Department of Nephrology, Chang Gung Memorial Hospital, Chiayi 613, Taiwan.
Abstract:
Chronic kidney disease (CKD) is a serious public health problem. Due to a high variability in the speed of CKD progression to end-stage renal disease (ESRD) and the critical involvement of Wnt/β-catenin signaling in CKD, we investigated the role of the Wnt antagonist Dickkopf-1 (DKK1) in CKD progression. Our data revealed that patients with CKD stages 4-5 had higher DKK1 levels in their serum and renal tissues than the control subjects. In an 8-year follow-up, the serum DKK1-high group in the enrolled CKD patients showed a faster progression to ESRD than the serum DKK1-low group. Using a rat model of 5/6 nephrectomy (Nx)-induced CKD, we consistently detected elevated serum levels and renal production of DKK1 in 5/6 Nx rats compared to sham-operated rats. Importantly, the knockdown of the DKK1 levels in the 5/6 Nx rats markedly attenuated the CKD-associated phenotypes. Mechanistically, we demonstrated that the treatment of mouse mesangial cells with recombinant DKK1 protein induced not only the production of multiple fibrogenic proteins, but also the expression of endogenous DKK1. Collectively, our findings suggest that DKK1 acts as a profibrotic mediator in CKD, and elevated levels of serum DKK1 may be an independent predictor of faster disease progression to ESRD in patients with advanced CKD.
Insights
Elevated Dickkopf-1 (DKK1) levels indicate faster chronic kidney disease (CKD) progression to end-stage renal disease (ESRD). DKK1 acts as a profibrotic mediator in CKD, suggesting it
Area of Science:
- Nephrology
- Molecular Biology
- Biochemistry
Background:
- Chronic kidney disease (CKD) is a significant global health issue.
- Wnt/β-catenin signaling plays a critical role in CKD pathogenesis.
- Variability in CKD progression necessitates identification of predictive markers.
Purpose of the Study:
- To investigate the role of the Wnt antagonist Dickkopf-1 (DKK1) in CKD progression.
- To determine if serum DKK1 levels can predict the rate of progression to end-stage renal disease (ESRD).
Main Methods:
- Serum and renal tissue DKK1 levels were measured in CKD patients (stages 4-5) and controls.
- An 8-year follow-up study assessed CKD progression in relation to baseline DKK1 levels.
- A rat model of 5/6 nephrectomy (Nx)-induced CKD was used to evaluate DKK1's role in vivo.
- DKK1 knockdown was performed in the rat model.
- Mouse mesangial cells were treated with recombinant DKK1 to assess its effects on fibrogenic protein production.
Main Results:
- CKD patients (stages 4-5) exhibited higher serum and renal DKK1 levels compared to controls.
- Higher serum DKK1 levels correlated with faster progression to ESRD in CKD patients.
- 5/6 Nx rats showed elevated serum and renal DKK1.
- DKK1 knockdown in 5/6 Nx rats attenuated CKD phenotypes.
- Recombinant DKK1 induced fibrogenic protein production and endogenous DKK1 expression in mouse mesangial cells.
Conclusions:
- DKK1 functions as a profibrotic mediator in the context of CKD.
- Elevated serum DKK1 is a potential independent predictor of accelerated CKD progression to ESRD in advanced stages.
Related Concept Videos
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease III: Interprofessional Care
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Nephrons

